TrialThe journal of headache and pain2022

Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.

Richard B Lipton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.